AcelRX Pharmaceuticals closed a $25 million senior secured debt facility, hoping to capitalize on the "high level of interest" its product has garnered from ASCs and other providers.
Three quick details:
1. AcelRx plans to use the senior secured debt facility with Oxford Finance to commercially launch DSUVIA and repay $9 million outstanding under a previous senior credit facility.
2. DSUVIA is a sufentanil sublingual tablet indicated for the management of acute pain severe enough to require an opioid analgesic.
3. AcelRx is hiring hospital account managers to field interest in DSUVIA from hospitals, ASCs and government entities, CEO Vince Angotti said in a press release.